Design Therapeutics, Inc. (DSGN)

Every figure this model derived for DSGN, the value it took, and the element in the company's own XBRL it was read from — so any of it can be checked against the filing rather than taken on trust. As at 2026-06-30.

The figures, and where each came from

This is the part no other screener shows. Each figure below names the XBRL element it was read from, so it can be checked against the filing itself.

FigureValueXBRL tagAs at
capex 55,000 PaymentsToAcquirePropertyPlantAndEquipment 2026-06-30
cash 207,396,000 CashAndCashEquivalentsAtCarryingValue 2026-06-30
current assets 212,013,000 AssetsCurrent 2026-06-30
current liabilities 11,240,000 LiabilitiesCurrent 2026-06-30
equity 201,858,000 StockholdersEquity 2026-06-30
ocf -55,083,000 NetCashProvidedByUsedInOperatingActivities 2026-06-30
revenue 0 Revenues 2026-06-30
sbc 14,816,000 ShareBasedCompensation 2026-06-30

The ratios

The figures themselves rather than their scores — what somebody looking up DSGN on one particular measure came for.

RatioValue
current ratio18.86
current ratio reported18.86
dilution pct1.31

What to be careful about

What this model itself distrusts about DSGN's figures. Written by the derivation as it ran, not added afterwards.